ReviewRheumatology (Oxford, England)2015
Old medications and new targeted therapies in systemic sclerosis.
Review in Rheumatology (Oxford, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Efficacy of cyclophosphamide for skin fibrosis in systemic sclerosis: a systematic review and single-arm meta-analysis.European journal of clinical pharmacology · 2025Pooled it
- Stem cell transplantation for systemic sclerosis.The Cochrane database of systematic reviews · 2022Pooled it
- IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases.International journal of molecular sciences · 2019Pooled it
- Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.Current opinion in rheumatology · 2015Pooled it
- Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.Arthritis care & research · 2018Trial
- Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).Annals of the rheumatic diseases · 2018Trial
- Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2018Trial
- Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis.Bone marrow transplantation · 2017Trial
- Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials.Arthritis research & therapy · 2015Trial
- Evolution of Systemic Sclerosis-Associated Interstitial Lung Disease One Year After Hematopoietic Stem Cell Transplantation or Cyclophosphamide.Arthritis care & research · 2022Observational
- [Expression of pituitary tumor-transforming gene-1 and its pathogenic role in systemic sclerosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- Article
- Invariant natural killer T cells are functionally impaired in patients with systemic sclerosis.Arthritis research & therapy · 2019Article
- Severe gangrene in a patient with anti-RNP positive limited cutaneous systemic sclerosis/rheumatoid arthritis overlap syndrome caused by vasculopathy and vasculitis.European journal of rheumatology · 2018Article
- Existing and novel biomarkers for precision medicine in systemic sclerosis.Nature reviews. Rheumatology · 2018Review
- Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis.Frontiers in immunology · 2018Review
- TRPV4 ion channel is a novel regulator of dermal myofibroblast differentiation.American journal of physiology. Cell physiology · 2017Article
- Rituximab in early systemic sclerosis.RMD open · 2017Article
- Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?The Journal of rheumatology · 2016Article
- Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment.Current treatment options in rheumatology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
SSc is a multiorgan disease with significant morbidity that is associated with poor health-related quality of life. Treatment of this condition is often organ based and non-curative. However, there are newer, potentially disease-modifying therapies available to treat certain aspects of the disease. This review focuses on old and new therapies in the management of SSc in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.